Prima BioMed Share Holder Equity 2010-2021 | IMMP
Prima BioMed share holder equity from 2010 to 2021. Share holder equity can be defined as the sum of preferred and common equity items
Prima BioMed Annual Share Holder Equity
(Millions of US $) |
| 2021 |
$55 |
| 2020 |
$22 |
| 2019 |
$17 |
| 2018 |
$26 |
| 2017 |
$20 |
| 2016 |
$26 |
| 2015 |
$21 |
| 2014 |
$19 |
| 2013 |
$30 |
| 2012 |
$38 |
| 2011 |
$55 |
| 2010 |
$15 |
| 2009 |
$1 |
Prima BioMed Quarterly Share Holder Equity
(Millions of US $) |
| 2017-03-31 |
$22 |
| 2016-12-31 |
$23 |
| 2016-06-30 |
$26 |
| 2015-12-31 |
$31 |
| 2015-06-30 |
$21 |
| 2014-12-31 |
$20 |
| 2014-06-30 |
$19 |
| 2013-12-31 |
$28 |
| 2013-06-30 |
$30 |
| 2012-12-31 |
$30 |
| 2012-06-30 |
$38 |
| 2011-06-30 |
$55 |
| 2010-06-30 |
$15 |
| 2009-06-30 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.174B |
$0.003B |
|
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
|
